Going Mobile - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Going Mobile
Seven Reasons Why Pharmaceutical Makers Are Adopting Mobile Technology

Pharmaceutical Technology

When companies end their dependence on paperwork, they typically experience productivity increases of 10–25% (2). They also see an improvement in first-time fix rates because their skill teams have more data at the point of performance. The labor savings and increase in productivity easily offset the initial investment costs.

Deploying multiple mobile products that use a single platform technology decreases application costs and results in exponential increases in data for better management.


In the pharmaceutical industry, the adoption of mobile technology is an ongoing trend. Organizations are adopting mobile technology to remain competitive. The seven reasons why mobile technology is taking off in the pharmaceutical industry are straightforward and time-tested. New uses for the technology continue to emerge as operational and organizational experts are exposed to the software and users see its convenience.

Richard W. Padula is president and chief executive officer of Syclo, 1721 Moon Lake Blvd., Suite 300, Hoffman Estates, IL 60169, tel. 847.230.3800,


1. C. Garritty and K. El Emam, "Who's Using PDAs? Estimates of PDA Use by Health Care Providers: A Systematic Review of Surveys," J. Med. Internet Res. 8 (2), e7 (2006).

2. Syclo, "Syclo Mobile Results Customer Survey" (Syclo, Hoffman Estates, IL, 2004).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here